JUN 04, 2021 4:13 PM PDT

Tiny Bone Marrow Models Help Tailor Treatments for Platelet Disorder Patients

WRITTEN BY: Tara Fernandez

Scientists have developed miniaturized 3-dimensional bone marrow models that could help physicians to predict which patients would likely respond to therapies for blood platelet disorders.

Thrombocytopenic disorders are inherited conditions where the production of platelets—blood cells that circulate and bind when they sense blood vessel damage—are dysregulated. Patients with insufficient platelets are prone to internal hemorrhaging or uncontrolled bleeding after an injury. In these cases, patients are administered a drug called Eltrombopag.

The problem, says the study’s first author Christian Di Buduo, is that not all thrombocytopenia patients respond to Eltrombopag in the same way.

Di Buduo and their team created a miniature tissue-engineered model of the human bone marrow which consisted of a silk protein scaffold housing patient-derived bone marrow cells. "This device is a significant improvement over previous models, requiring only a very small sample of blood to recreate platelet production," Di Buduo said.

“Patients with the same apparent form of thrombocytopenia may respond differently to the treatment,” wrote the authors. “We describe a miniaturized bone marrow tissue model that provides a screening bioreactor for personalized, pre-treatment response prediction to eltrombopag for individual patients. Using silk fibroin, a 3D bone marrow niche was developed that reproduces platelet biogenesis.”

To validate their model, they obtained samples from a patient previously treated with Eltrombopag and showed that the number of platelets produced in the bone marrow cultures matched the patient’s response.

According to Di Buduo and colleagues, this development can help clinicians tailor platelet disorder treatments, making sure patients’ conditions are managed more effectively. In addition, they say that this model also represents a research tool that could pave the way for new and improved therapies to manage platelet disorders in the future.


Sources: GEN, eLife.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 12, 2021
Clinical & Molecular DX
Computers Pick Up the 'Sound' of Thyroid Cancer
AUG 12, 2021
Computers Pick Up the 'Sound' of Thyroid Cancer
Researchers have developed a new technology for the non-invasive diagnosis of thyroid cancer that combines photoacoustic ...
AUG 31, 2021
Clinical & Molecular DX
Five Questions to Help You Select the Best Cellular Stain
AUG 31, 2021
Five Questions to Help You Select the Best Cellular Stain
Cellular stains are organic fluorescent dyes or fluorescent conjugates designed to localize to a specific organelle or c ...
SEP 14, 2021
Clinical & Molecular DX
HIV Self-Test App Proves Promising
SEP 14, 2021
HIV Self-Test App Proves Promising
A new app allows users to self-test for HIV, which has proven to help positive patients get access to medical care and c ...
OCT 26, 2021
Clinical & Molecular DX
AI Diagnostic Looks for Bad Blood
OCT 26, 2021
AI Diagnostic Looks for Bad Blood
Blood cells originate from stem cell progenitors in the bone marrow, differentiating into an array of specialized cell t ...
DEC 02, 2021
Clinical & Molecular DX
Gut Bacteria Slip Into the Pancreas, Cause Cancer
DEC 02, 2021
Gut Bacteria Slip Into the Pancreas, Cause Cancer
  Scientists have connected the dots between bacteria in the digestive system and an increased risk of malignant pa ...
DEC 01, 2021
Cardiology
Is GDF-15 a Valuable Biomarker for Congestive Heart Failure?
DEC 01, 2021
Is GDF-15 a Valuable Biomarker for Congestive Heart Failure?
Congestive Heart Failure (CHF) is a serious medical condition that results in the heart not being able to pump to meet t ...
Loading Comments...